OBJECTIVES: Sequential antyhelicobacter therapy (A") is one of the ways to overcome Helicobacter pylori (H. pylori) resistance to antibiotics. The aim is compare the cost effectiveness ratio of different schemes of AT of first line: a sequential therapy (scheme 1) and traditional triple therapy (scheme 2). METHODS: Cost-effectiveness analysis was used. The schemes and their efficacy were taken from a clinical study which were conducted in a hospital in Kharkiv (Babak O.J., 2009). This trial involved 63 patients with peptic ulcers of the duodenum (PUD) associated with H. pylori. Scheme 1: the drugs were prescribed in 2 stages: the first (5 days) - rabeprazole (daily dose (DD) 40 mg), amoxicillin (DD 2000 mg), the second (5 days) – rabeprazole (DD 40 mg), clarithromycin (DD 1000 mg) and bismuthate tripotassium dicitrate (DD 480 mg). Scheme 2 included of rabeprazole (DD 40 mg), amoxicillin (DD 2000 mg), clarithromycin (DD 1000 mg) for 10 days. After administration of both schemes, the patients received rabeprazole (DD 20 mg) for one month. A criterion of efficacy was the number of patients (%) with H. pylori eradication: scheme 1 – 96.80%, scheme 2 – 72.00%. For determining the costs of the course of AT per patient only the costs of the drugs were taken into account. The prices of drugs were taken from the information system "Drugs" of Company "Morion" (February, 2012). The currency ratio of UAH to dollar (USA) on 01.02.12 was 7.98:1. RESULTS: The costs for the scheme 1 are 170.28 $, for scheme 2 are  202.29$. The first scheme (ÑER 175.91$) 1.6 times is more cost effective than the scheme 2 (ÑER 280.96$). CONCLUSIONS: The application of sequential antyhelicobacter therapy can provide effective and economically founded AT PUD in medical practice.